Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors


The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

“We learned [in a previous study] that the immune engager to the NK cell is critically important. And while that study was ongoing, we discovered that if we took a nanobody, single domain antibody to engage CD16, we had significantly greater potency. So that's really the premise for putting this together.”

GTB-5550, a B7H3 tri-specific killer engager (TriKE) specifically stimulated expansion of natural killer (NK) cells in preclinical models of multiple cancers. These data were presented at the European Society of Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France, by Jeffrey Miller, MD, professor and deputy director of the Masonic Cancer Center of the University of Minnesota.

GTB-5550 is a novel dual camelid (cam) TriKE that contains wild type interleukin-15 as well as 2 cam engagers to target CD16 on NK cells and B7H3 on multiple solid tumors. Miller and colleagues demonstrated increased activity of NK cells against cancer cells after stimulation with the TriKE engager.

CGTLive spoke with Miller to learn more about the study’s results and the importance of improving targeting and engagement of NK cells with antibodies. He also discussed the potential for a clinical trial in the near future investigating the approach.

Click here to read more coverage of ESMO Congress 2022.

Miler JS, Zorko N, Merino A, et al. B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Presented at: ESMO Congress 2022, September 9-13, Paris, France.
Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.